Analysis of the medical insurance inclusion status of Sotoraxibu and purchasing guide

Sotoracib, a targeted drug specially designed for patients with advanced non-small cell lung cancer (NSCLC) carrying the KRAS G12C mutation, has attracted much attention since its introduction. KRAS G12CMutation is quite common in lung cancer and is difficult to treat. As a pioneer of KRAS G12C inhibitors, sotoracib effectively inhibits the growth of cancer cells by precisely inhibiting KRAS G12C protein activity, bringing significant progression-free survival to patients and filling a gap in treatment in this field.

However, for domestic patients, sotorasibu is not currently on the market and is therefore not included in China’s medical insurance system. This means that patients cannot purchase the drug through formal domestic channels and must obtain it through overseas channels. In overseas markets, the original drug of sotorasibu is expensive. Taking the European version and the Hong Kong version as examples, the price is often as high as tens of thousands of yuan, which puts heavy financial pressure on patients.

Fortunately, with the rapid development of the generic drug market, generic drugs of sotorasibu have emerged in some countries and regions. Especially in Laos, the generic drugs of sotorasibu launched by brands such as Lucius and Daxiong Pharmaceutical are not only more affordable, but have also been lowered recently, with the price range ranging from more than one thousand yuan to more than two thousand yuan. These generic drugs have the same active ingredients as the original drugs, providing patients with a more cost-effective treatment option.

Faced with the current situation that it has not yet been launched in the country, many patients choose to purchase generic drugs of sotorasibu from overseas markets such as Laos and India to meet their treatment needs. With the widespread application and recognition of sotorasibu around the world, its prospects for listing in China have become increasingly clear. Once it is launched in the future, the possibility of being included in medical insurance will also increase significantly, which will greatly reduce the financial burden on patients and allow more patients to benefit from this innovative drug.